Measuring Alzheimer's disease progression with transition probabilities in the Taiwanese population

International Journal of Geriatric Psychiatry

Volumn 19, Issue 3, 2004, Pages 266-270

  Fuh, Jong Ling ^a   Pwu, Raoh Fang ^b   Wang, Shuu Jiun ^a   Chen, Yu Hsin ^b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b Stat Healthcare Consulting Co Ltd   (Taiwan)

Author keywords

Alzheimer's disease; Clinical dementia rating scale; Dementia; Transition probability

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; RIVASTIGMINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BEHAVIOR DISORDER; CONTROLLED STUDY; DEATH; DELUSION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FOLLOW UP; GROUPS BY AGE; GROUPS BY SEX; HALLUCINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PROBABILITY; RISK ASSESSMENT; SEX RATIO; SURVIVAL RATE; TAIWAN; WESTERN HEMISPHERE;

AGE FACTORS; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; PROBABILITY; PROPORTIONAL HAZARDS MODELS; SEX FACTORS; TAIWAN;

EID: 1642446213     PISSN: 08856230     EISSN: None     Source Type: Journal    
DOI: 10.1002/gps.1076     Document Type: Article

References (15)

1. Farlow MR, Hake A, Messina J, Hartman R, Veach J, Anand R. 2001. Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression. Arch Neurol 58(3): 417-422.
2. Heyman A, Peterson B, Fillenbaum, G, Pieper C. 1996. The consortium to establish a registry for Alzheimer's disease (CERAD). Part XIV: Demographic and clinical predictors of survival in patients with Alzheimer's disease. Neurology 46(3): 656-660.
3. Knopman D, Schneider L, Davis K, et al. 1996. Long-term tacrine (Cognex) treatment: Effects on nursing home placement and mortality, Tacrine Study Group. Neurology 47(1): 166-177.
4. Liu CK, Lin RT, Chen YF, Tai CT, Yen YY, Howng SL. 1996. Prevalence of dementia in an urban area in Taiwan. J Formos Med Assoc 95(10): 762-768.
5. Liu HC, Chou P, Lin KN, et al. 1994. Assessing cognitive abilities and dementia in a predominantly illiterate population of older individuals in Kinmen. Psychol Med 24(3): 763-770.
6. Liu HC, Lin KN, Teng EL, et al. 1995. Prevalence and subtypes of dementia in Taiwan: A community survey of 5297 individuals. J Am Geriatr Soc 43(2): 144-149.
7. Lopez OL, Becker JT, Wisniewski S, Saxton J, Kaufer DI, DeKosky ST. 2002. Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease. J Neurol Neurosurg Psychiatry 72(3): 310-314.
8. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. 1984. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34(7): 939-944.
9. Mohs RC, Doody RS, Morris JC, et al. on behalf of the '312' Study Group. 2001. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 57(3): 481-488.
10. Morris JC. 1993. The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology 43(11): 2412-2414.
11. Mortimer JA, Ebbitt B, Jun SP, Finch MD. 1992. Predictors of cognitive and functional progression in patients with probable Alzheimer's disease. Neurology 42(9): 1689-1696.
12. Neumann PJ, Araki SS, Arcelus A, et al. 2001. Measuring Alzheimer's disease progression with transition probabilities: Estimates from CERAD. Neurology 57(6): 957-964.
13. Rogers SL, Friedhoff LT. 1996. The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial. The Donepezil Study Group. Dementia 7(6): 293-303.
14. Rosler M, Anand R, Cicin-Sain A, et al. 1999. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 318(7184): 633-638.
15. Storandt M, Grant EA, Miller JP, Morris JC. 2002. Rates of progression in mild cognitive impairment and early Alzheimer's disease. Neurology 59(7): 1034-1041.